IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS

• US 20130084243A1
• Filed: 11/29/2012
• Published: 04/04/2013
• Est. Priority Date: 01/27/2010
• Status: Abandoned Application

• Current Assignee: David Brooks, Liliane Goetsch, Michael Chastain, Nathalie Corvaia, Zhi-Qiang Zhang
• Original Assignee: David Brooks, Liliane Goetsch, Michael Chastain, Nathalie Corvaia, Zhi-Qiang Zhang
• Inventors: Zhang, Zhi-Qiang, Chastain, Michael, Corvaia, Nathalie, Brooks, David, Goetsch, Liliane
• Application Number:
  US13/688,574
• Publication Number:
  US 20130084243A1
• Time in Patent Office: Days
• US Class Current: 424/1.49
• CPC Class Codes: A61K 51/103 against receptors for growth factors or receptors for growth regulators
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 2333/72 for hormones for neuromediators G01N2333/70571
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/56 Staging of a disease; Further complications associated with the disease
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.

Claims

1. An antibody or an antigen-binding portion thereof that specifically binds insulin-like growth factor I receptor (IGF-IR), comprising at least one light chain sequence and at least one heavy chain sequence, wherein said light chain comprises at least one complementarity determining region (CDR) selected from the group consisting of the amino acids sequences as set forth in SEQ ID NO. 1, 2, or 3, or at least one CDR comprising an amino acid sequence having at least 80% identity with the sequence set forth in SEQ ID NO. 1, 2, or 3, and wherein said heavy chain comprises at least one complementarity determining region (CDR) selected from the group consisting of the amino acids sequences as set forth in SEQ ID NO. 4, 5 or 6, or at least one CDR comprising an amino acid sequence having at least 80% identity after with the sequence set forth in SEQ ID NO. 4, 5 or 6.

2. The antigen-binding portion according to claim 1, wherein said portion is selected from the group consisting of:

a Fab fragment, an F(ab′

)₂ fragment and an Fv fragment.

3. The antibody according to claim 1, wherein said light chain comprises the amino acid sequence as set forth in SEQ ID NO:

7 and said heavy chain comprises the amino acid sequence as set forth in SEQ ID NO;

8.

7. A method for diagnosing an oncogenic disorder associated with expression of IGF-1R or determining the prognosis for developing an oncogenic disorder associated with expression of IGF-1R in a subject comprising contacting a sample from the subject with the monoclonal antibody of claim 1, and detecting the binding of the monoclonal antibody with the sample, wherein binding of the monoclonal antibody to the sample is indicative of the diagnosis of said neoplasia.

8. A method of detecting the presence or location of an IGF-IR-expressing tumor in a subject, comprising the steps of:

a) administering the antibody or antigen-binding portion according to claim 1 to the subject; and

b) detecting binding of said antibody, wherein said binding indicates the presence or location of the tumor.

9. A method for determining the prognosis of the course of a malignant disease associated with expression of IGF-1R, comprising obtaining a sample from a subject suspected of containing tumor cells, contacting said sample with the antibody of claim 1 or an antigen-binding fragment thereof, wherein binding of the antibody or the antigen-binding fragment thereof with tumor cells in the sample is indicative of a tumor and gives a prognoses for the course of a malignant disease in said subject.

12. A method for following progress of a therapeutic regime designed to alleviate an oncogenic disorder associated with or characterized by expression of IGF-1R comprising:

(a) assaying a biological sample from a subject to determine level of IGF-1R at a first time point by contacting said sample with the antibody according to claim 1;

(b) assaying level of IGF-1R at a second time point; and

(c) comparing said level at said second time point to the level determined in (a) as a determination of effect of said therapeutic regime.

13. A method for determining the expression of an IGF-1R polypeptide (a) in a test tissue sample suspected of containing said polypeptide and (b) a control normal tissue sample of the same tissue type, said method comprising exposing the test and control tissue samples to the anti-IGF-1R antibody of claim 1 and determining the relative binding of said antibody to said polypeptide in each of said samples.

14. The method according to claim 13, further comprising quantifying the level of IGF-1R expression in said control sample to obtain a normal or control value and comparing the same to the level obtained in the test tissue sample to determine the overall expression of IGF-1R in said test tissue sample.

22. A method for determining onset, progression, or regression, of an oncogenic disorder associated with expression of IGF-1R in a subject, comprising:

(i) (a) obtaining from a subject a first biological sample,

(b) contacting the first sample with a therapeutically effective amount of a therapeutic anti-IGF-1R antibody sufficient to down regulate IGF-1R expression, wherein said antibody is other than the antibody of claim 1;

(c) determining specific binding between the antibody in the first sample and IGF-1R bearing cells,

(ii) (a) obtaining subsequently from the subject a second biological sample,

(b) contacting the second biological sample with the antibody of claim 1,

(c) determining specific binding between the antibody in the second sample and IGF-1R bearing cells, and

(iii) comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of the neoplasia.

23. A method for monitoring the efficacy of an antibody in correcting an abnormal level of IGF-1R in a subject presenting with an oncogenic disorder associated with increased of IGF-1R, comprising

i) administering an effective amount of a conventional IGF-1R antibody other than the antibody of claim 1 to said subject;

and

ii) determining a level of IGF-1R in said subject following the administration of the conventional antibody, wherein a change in the level of IGF-1R towards a normal level is indicative of the efficacy of said antibody.

24. The method according to claim 23 wherein step (ii) comprises contacting a tissue sample obtained from said subject with the antibody according to claim 1 under conditions favoring the formation of a complex between IGF-1r expressing cells and said antibody and detecting said complex as a determination of the expression level of IGF-1R in said sample.

25. A method for diagnosing pediatric soft tissue tumors based on differential expression of IGF-1R, said method comprising:

a) obtaining a biological sample from a pediatric patient;

b) contacting said sample with the antibody or antigen-binding fragment according to claim 1 and;

c) determining presence of IGF-1R as indicated by localization of said antibody or antigen-binding fragment immunologically specific for IGF-1R, wherein elevated IGF-1R staining provides a positive diagnostic indicator of said soft tissue tumor.

26. The method as claimed in claim 25, wherein said antibody comprises a detectable label.

27. The method as claimed in claim 26, wherein said detectable label is selected from the group consisting of fluorescein, rhodamine, phycoerythrin, biotin, and strepavidin.

28. The method as claimed in claim 25, wherein said antibody is detected by a method selected from the group consisting of flow cytometric analysis, immunochemical detection and immunoblot analysis.

29. The method of claim 26, wherein said antibody or fragment is in solution.

30. The method as claimed in claim 25, wherein said biological sample comprises soft tissue tumor cells and non-malignant cells.

31. The method of claim 30, wherein said biological sample comprises one of rhabdomyosarcoma cancer cells, osteosarcoma cells cr, ewings sarcoma cells.

33. The article of manufacture according to claim 32, wherein said active ingredient comprises the antibody according to claim 1.

34. An in vivo method of imaging an oncogenic disorder associated with expression of IGF-1R comprising the steps of:

(a) administering to a subject an imaging-effective amount of the labeled monoclonal antibody according to claim 1 or fragment thereof and a pharmaceutically effective carrier; and

(b) detecting the binding of said labeled monoclonal antibody or fragment thereof to IGF-1R expressing cells associated with said disorder.

35. The method of claim 34, wherein said monoclonal antibody or fragment thereof is radiolabeled.

36. The method of claim 34, wherein said detecting involves radioactive imaging.

38. A method of producing the monoclonal antibody of claim 1 comprising immunizing Balb/c mice with an IGF-1R dependent mouse hematopoetic cell transfectants that expresses human IGF-1R at the cell surface.

39. A pharmaceutical composition for in vivo imaging of an oncogenic disorder associated with expression of IGF-1R comprising the monoclonal antibody of claim 1 or an antigen binding fragment thereof which is labeled and which binds IGF-1R in vivo;

and a pharmaceutically acceptable carrier.

40. A method for detecting IGF-1R or one of its isoforms or a fragment thereof in a biological sample, comprising:

(a) contacting said biological sample the antibody of claim 1 thereby forming an antibody-polypeptide complex; and

(b) detecting said antibody-polypeptide complex as indicating presence of said IGF-1R in said sample.

41. The method according to claim 40, wherein said antibody is detectably labeled.

42. An immunoassay method for analysis of a sample, comprising the steps of:

a. contacting the sample with the monoclonal antibody according to claim 1; and

b. detecting the presence of IGF-1R in said sample.

43. The method of claim 42 in which said immunoassay is selected from the group comprising:

direct, indirect, capture, competitive binding, and displacement.

44. The method of claim 42 in which said step of detecting the presence of IGF-1R comprises a qualitative analysis.

45. The method of claim 42 in which said step of detecting the presence of IGF-1R comprises a quantitative analysis.

46. The method of claim 42 in which said binding assay comprises a clinical diagnostic assay.

47. The method of claim 42 which is of the type selected from the group consisting of:

IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

48. A method for diagnosing an oncogenic disorder associated with expression of IGF-1R comprising:

a) measuring by radioimmunoassay, competitive-binding assay, Western blot analysis, ELISA assay, or sandwich assay the amount of IGF-1R protein in a sample obtained from a patient, using an antibody that specifically binds to IGF-1R; and

b) comparing the amount of antibody bound to said IGF-1R protein to a normal control tissue sample, wherein increased expression or over-expression of IGF-1R in the sample obtained from the patient relative to the normal control tissue sample is diagnostic of an oncogenic disorder associated with expression of IGF-1R, wherein said antibody is as described in claim 1.

49. The method of claim 48, wherein said sample obtained from a patient is tissue biopsy.

4. A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR) or an antigen-binding portion of said antibody, wherein the antibody or antigen-binding portion comprises the amino acid sequences of at least one CDR selected from the group consisting of CDR1, CDR2 and CDR3 regions found in the variable domain of a light chain as set forth in SEQ ID NO:

7 and the amino acid sequences of at least one CDR selected from the group consisting of CDR1, CDR2 and CDR3 regions found in the variable domain of a heavy chain as set forth in SEQ ID NO;

8.

5. A hybridoma cell line deposited at the Centre National de Culture De Microorganisme (CNCM, National Center of Microorganism Culture) (Institut Pasteur, Paris, France) under the number I-3538.

6. The cell line according to claim 5, wherein said cell line produces an antibody comprising a light chain as set forth in SEQ ID NO. 7 and a heavy chain comprising amino acid sequence SEQ ID NO. 8.

10. A method for selecting a therapy for a patient or a patient population with a tumor associated with or mediated by expression of IGF-1R comprising:

(a) determining whether the patient'"'"'s tumor is known to over express IGF-1R bearing cells relative to normal and (b) selecting an IGF-1R inhibitory agent as the therapy if the patient'"'"'s tumor is known to over express said IGF-1R.

11. The method of claim 10, wherein the agent is:

(i) an isolated antibody or antigen-binding fragment thereof that binds specifically to human IGF-1R comprising one or more CDRs from a light chain variable region comprising amino acids as set forth in SEQ ID NO;

7 or (ii) one or more CDRs from a heavy chain variable region comprising amino acids as set forth in SEQ ID NO;

8;

or (iii) an isolated single-chain antibody (scfv) that binds specifically to human IGF1R.

15. A method for determining the prognosis for survival for a patient presenting with a sarcoma selected from the group consisting of osteosarcoma, neuroblastoma, Ewings sarcoma and Rhabdomyo-sarcoma, comprising:

(a) measuring a level of IGF-1R polypeptide in a cancer cell-containing sample from said patient, and (b) comparing the level of IGF-1R polypeptide in said sample to a reference level of IGF-1R polypeptide from normal tissue, wherein a lower level of IGF-1R polypeptide relative to said reference level correlates with increased survival of said patient.

16. A method for prognostic evaluation of a patient suspected of exhibiting an oncogenic disorder associated with expression of IGF-1R comprising:

(a) determining the concentration of IGF-1R present in a biological sample, taken from the patient, suspected of containing oncogenic tissue;

(b) comparing the level determined in step (a) to the concentration range of IGF-1R polypeptide known to be present in normal, non-oncogenic tissue of the same type as present in the biological sample; and

(c) evaluating the prognosis of said patient based on the comparison in step (b), wherein a high level of IGF-1R in step (a) indicates an aggressive form of cancer and therefore a poor prognosis.

17. The method according to claim 16 further comprising a step prior to step (a) comprising purifying said IGF-1R polypeptide from the biological sample.

18. The method of claim 17 wherein the purifying method is immunoaffinity chromatography.

19. A method for determining the prognosis of an individual with an oncogenic disorder or a susceptibility to a pathological hyperproliferative disorder associated with expression of IGF-1R in a subject, comprising:

a) determining the expression levels of IGF-1R in a biological sample collected from said patient in different states of the individual; and

b) comparing the expression profile of IGF-1R in the different states, wherein a higher level of the expression in a later state compared with an early state indicates a poor prognosis.

20. A method of detecting a pathological hyperproliferative oncogenic disorder associated with expression of IGF-1R in a subject comprising:

a) determining the level of expression of IGF-1R in a first tissue sample obtained from said first individual; and

b) comparing said level obtained in step (a) with that of a normal tissue sample obtained from said first individual or a second unaffected individual;

wherein a difference in said expression of IGF-1R is an indication that the first individual may present have said pathological hyperproliferative oncogenic disorder.

21. The method according to claim 20, wherein said difference is an increase in the expression level of IGF-1R relative to the normal tissue.

32. An article of manufacture, comprising:

a container;

a label on the container; and

a composition comprising an active agent contained within the container, wherein the composition is effective for detecting IGF-1R in neoplastic tissue or dysplastic cells and wherein the label on the container indicates that the composition is effective for diagnosing conditions associated with expression of IGF-1R polypeptide in said neoplastic tissue compared to normal tissue.

37. A method for determining whether a cancer is susceptible to treatment with an anti-neoplastic agent comprising the steps of:

(a) obtaining a sample of the cancer, (b) measuring the level of IGF-1R in the sample, (c) comparing the level with a predetermined value, and (d) determining that, if the measured level is larger than the predetermined value, the cancer is susceptible to treatment with the anti-neoplastic agent.

50. A diagnostic or monitoring method comprising:

a) obtaining a sample of tissue from an individual in need of diagnosis or monitoring for cancer;

b) detecting levels of IGF-1R protein in said sample, c) scoring said sample for IGF-1R protein levels; and

d) comparing said scoring to that obtained from a control tissue sample to determine the prognosis associated with said cancer.

51. The diagnostic or monitoring method according to claim 50, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells and wherein a score of 1 to 4 indicates a poor prognosis while a score of 0 indicates a good prognosis.

52. The diagnostic or monitoring method of claim 50 wherein said cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, pancreatic cancer, colon cancer, ovarian cancer, ewings sarcoma, rhabdomyosarcoma, neuroblastoma or osteosarcoma.

53. The diagnostic or monitoring method according to claim 50, wherein the step of detecting levels of IGF-1R comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody comprises 12B1 or an antigen binding fragment thereof.

54. The diagnostic or monitoring method according to claim 53, wherein the detecting or measuring step is selected from the group of methods consisting of immunoblotting, immunohistochemistry and immunocytochemistry.

55. The diagnostic or monitoring method according to claim 50 wherein the step b) is done by Fluorescence-Activated Cell Sorting (FACS).

56. A method for determining a chemotherapeutic regimen comprising an IGF-1R targeted agent, for treating a tumor in a patient comprising:

(a) obtaining a tissue sample of the tumor;

(b) detecting levels of IGF-1R levels in said sample, (c) scoring said sample for expression of IGF-1R levels, (d) repeating steps (b)-(c) in a matching non-malignant tissue sample to obtain a threshold level (e) determining a chemotherapeutic regimen by comparing the differential IGF-1R expression level of step (c) and the threshold level of step (d), wherein an increase in differential IGF-1R expression level in step (c) relative to step (d) dictate placing said patient in the chemotherapeutic regimen.

57. The method according to claim 56, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells and wherein a score of 1 to 4 (i.e. a positive score) indicates chemotherapeutic regimen.

58. The method according to claim 56, wherein the step of detecting levels of IGF-1R comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.

59. A method for predicting disease-free survival and overall survival in a patient with an oncogenic disorder associated with IGF-1R expression comprising:

a) obtaining a sample of diseased or cancerous tissue from an individual presenting with said oncogenic disorder, b) detecting levels of IGF-1R expressing cells in said cancer cells or cancer tissue of said sample;

c) scoring said samples for expression of IGF-1R levels; and

d) comparing said scoring to that obtained from a control sample to determine likelihood of disease-free survival and overall survival associated with IGF-1R.

60. The method according to claim 59, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells and wherein a score of 1 to 4 (i.e. a positive score) indicates a poor prognosis for disease free and overall survival in patients with said disorder.

61. The method according to claim 59, wherein the step of detecting levels of IGF-1R expressing cells comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.

62. A method for treating an IGF-1R mediated cancer comprising:

a) obtaining a sample of diseased tissue from a patient in need of treatment of said cancer;

b) determining the level of expression of IGF-1R levels in said tissue sample;

c) scoring said samples for expression of IGF-1R levels;

d) correlating said score to identify patients likely to benefit from treatment with an IGF-1R antagonist, wherein said step of correlating comprises comparing said scoring to that obtained from a control sample, e) treating said patient with a therapeutic regime known to improve the prognosis for said cancer;

f) repeating steps “

a” and

“

b”

, and g) adjusting the therapeutic regime known to improve the prognosis for said cancer;

h) repeating steps a-f as frequently as deemed appropriate.

63. The method according to claim 62, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells.

64. The method according to claim 62, wherein the step of detecting levels of IGF-1R comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.

65. A method for determining the effect of a therapeutic regimen for alleviating an IGF-1R mediated disorder, wherein said regimen comprises the use of an IGF-1R antagonist, the method comprising the steps of:

a) obtaining a cell or tissue sample from an individual undergoing said therapeutic regimen b) measuring the levels of IGF-1R in said cell or tissue sample;

c) scoring said sample for IGF-1R protein levels, and d) comparing said levels to that of a control sample to predict the responsiveness of said IGF-1R mediated disorder to said therapeutic regimen.

66. The method according to claim 65 wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells.

67. The method according to claim 65, wherein the step of detecting levels of IGF-1R comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.

68. A method for stratifying a patient presenting with an oncogenic disorder mediated by IGF-1R for a clinical trial comprising:

a) obtaining a tissue sample from said patient, b) detecting levels of IGF-1R protein in said sample, c) scoring said sample for IGF-1R protein levels; and

d) stratifying said patient for said clinical trial based on the results of the scoring step.

69. The method according to claim 68, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells.

70. The method according to claim 68, wherein the step of detecting levels of IGF-1R comprises contacting said sample with an antibody specific for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.

71. A method of classifying or staging a breast tumor characterized by expression of IGF-1R comprising the steps of:

i) providing a breast tumor sample, ii) detecting expression IGF-1R in the sample, iii) scoring the sample for IGF-1R expression level, and iv) classifying the tumor as belonging to a tumor subclass based on the results of the scoring step.

72. The method according to claim 71, wherein said scoring comprises using a scale of 0 to 4, where 0 is negative (no detectable IGF-1R or level of IGF-1R comparable to a control level), and 4 is high intensity staining in the majority of cells.

73. The method according to claim 71, wherein the step of detecting expression of IGF-1r comprises contacting said sample with an antibody having specificity for IGF-1R, wherein said antibody is 12B1 or an antigen binding fragment thereof.